A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
Completed
Lantheus Medical Imaging
Phase 3
2011-06-01
The primary objective of the study is to assess the diagnostic efficacy (specificity and
sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to
single photon emission computed tomography (SPECT) MPI in the detection of significant
coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a
documented history of Myocardial Infarction (MI).
Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
Withdrawn
Lantheus Medical Imaging
Phase 3
2012-11-01
The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to
determine if the study drug in PET imaging is better than SPECT imaging currently used for
this purpose.
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Recruiting
Pharmaceutical Product Development, LLC
Phase 3
2018-06-08
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz
(18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Recruiting
GE Healthcare
Phase 3
2018-06-08
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz
(18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
